Solenn Le-Guennec

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

The ACE Gene <i>I/D</i> Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition

Stephen Harrap, Christophe Tzourio, François Cambien et al. · Hypertension · 2003 · 139 citations · Full text

Life Sciences, Genetics, Pharmacology +17

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Paul G. Richardson, Michel Attal, Frank Campana et al. · Future Oncology · 2017 · 70 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Jean‐Yves Blay, Zsuzsanna Pápai, Anthony W. Tolcher et al. · The Lancet Oncology · 2015 · 66 citations

Medicine, Oncology, Pharmacology +12

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

Cora N. Sternberg, Iwona Skoneczna, Daniel Castellano et al. · Oncology · 2013 · 38 citations

Medicine, Oncology, Pharmacology +10